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Niemann-Pick type C1 (NPC1) disease is caused by a deleterious mutation in the Npc1
gene, causing lysosomal accumulation of unesterified cholesterol and sphingolipids.
Consequently, NPC1 disease patients suffer from severe neurovisceral symptoms which,
in the absence of effective treatments, result in premature death. NPC1 disease patients
display increased plasma levels of cholesterol oxidation products such as those enriched
in oxidized low-density lipoprotein (oxLDL), a pro-inflammatory mediator. While it has
been shown that inflammation precedes and exacerbates symptom severity in NPC1
disease, it is unclear whether oxLDL contributes to NPC1 disease progression. In
this study, we investigated the effects of increasing anti-oxLDL IgM autoantibodies
on systemic and neurological symptoms in an NPC1 disease mouse model. For
this purpose, Npc1nih mice were immunized with heat-inactivated S. pneumoniae, an
immunogen which elicits an IgM autoantibody-mediated immune response against
oxLDL. Npc1nih mice injected with heat-inactivated pneumococci displayed an improved
hepatic phenotype, including liver lipid accumulation and inflammation. In addition,
regression of motor skills was delayed in immunized Npc1nih. In line with these results,
brain analyses showed an improved cerebellar phenotype and neuroinflammation in
comparison with control-treated subjects. This study highlights the potential of the
pneumococcal immunization as a novel therapeutical approach in NPC1 disease. Future
research should investigate whether implementation of this therapy can improve life span
and quality of life of NPC1 disease patients.
Keywords: Niemann-Pick type C1, oxidized low-density lipoprotein, pneumococcal immunization, inflammation,
lipid metabolism
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INTRODUCTION
Niemann-Pick type C1 (NPC1) disease is a rare, fatal disorder
caused by mutations in the Npc1 gene which result in the
accumulation of unesterified cholesterol and glycosphingolipids
in late endosomes/early lysosomes (1–3). The earliest clinical
findings of NPC1 disease are mostly related to systemic
problems in the liver (neonatal jaundice, liver failure (4–
6)) and the spleen (splenomegaly and severe abdominal pain
resulting in splenectomies (7), and increased sensitivity to
spontaneous infections (8)). While, in most patients, the systemic
symptoms resolve over time, some develop severe systemic
problems resulting in premature death (4). Besides the systemic
manifestation of the disease, NPC1 disease is also characterized
by severe disturbances in the central nervous system leading to
the progressive impairment of motor and cognitive function (2).
In spite of significant advances in the development of therapeutic
interventions for NPC1 disease (9, 10), there is currently no
curative treatment available.
While lysosomal lipid accumulation is at the root of NPC1
disease, secondary pathological mechanisms such as oxidative
stress (11), apoptosis (12), and inflammation (13, 14) have
been shown to accompany and even contribute to NPC1
disease progression. Similarly, atherosclerosis and non-alcoholic
steatohepatitis (NASH) also feature the aforementioned disease
mechanisms (15, 16) and lysosomal lipid accumulation in
macrophages (17). These observations suggest a mechanistic
link between the pathological mechanisms of NPC1 disease,
atherosclerosis, and NASH. Of note, increasing anti-oxLDL
IgM autoantibody levels in the latter metabolic diseases
ameliorates the macrophage-mediated inflammatory reaction
(18–20). Relevantly, multiple research papers have described the
cholesterol oxidation products 7-ketocholesterol and cholestane-
3β, 5α, 6β-triol, two products abundantly present in oxLDL
(21, 22), as sensitive and specific blood-based biomarkers for
diagnosing NPC1 disease (6, 23, 24). However, whether these
cholesterol oxidation products contribute to NPC1 disease
progression has to our knowledge never been investigated.
Given the mechanistic overlap between the pathologies of
NPC1 disease and of the metabolic diseases atherosclerosis
and NASH, the aim of the current study was to determine
whether increasing anti-oxLDL IgM autoantibodies reduces
NPC1 disease symptoms. For this purpose, Npc1nih mice were
immunized with heat-inactivated Streptococcus pneumoniae.
Npc1nih mice are a well-established NPC1 disease model in which
a mutation inNpc1 leads to NPC1 truncation and loss of function
(25). This mouse model recapitulates some of NPC1 disease
most prominent features, including severe lysosomal cholesterol
accumulation in most organs and motor function deficits (26–
30). Immunization of mice using inactivated S. pneumoniae
Abbreviations: NPC1, Niemann-Pick type C1; NASH, non-alcoholic
steatohepatitis; oxLDL, oxidized low-density lipoprotein; PC, phosphorylcholine;
TLA, locomotor activity time; HE, hematoxylin and eosin; Cxcl10, C-X-C
motif chemokine 10; Ccl3, chemokine (C-C motif) ligand 3; Cd68, cluster of
differentiation 68; Ctsd, cathepsin D; Acat2, acetyl-CoA acetyltransferase 2;
Tnfα, tumor necrosis factor alpha; Ccl2, chemokine (C-C motif) ligand 2; Mip2,
macrophage inflammatory protein 2; BBB, blood brain barrier.
has been established as an effective approach to increase serum
titers of anti-oxLDL IgM autoantibodies by means of molecular
mimicry (18, 31). In line with our hypothesis, immunizedNpc1nih
mice showed reduced motor function decay over time, decreased
neuro- inflammation, and degeneration, reduced inflammation
in liver and spleen and an improvement in liver lipid metabolism.
These findings provide evidence for the involvement of anti-
oxLDL IgM autoantibodies in NPC1 disease progression and
highlight vaccination strategies leading to the elevation of anti-




For immunization, the heat-inactivated R36A strain of S.
pneumoniae (Birmingham, AL) was used, still bearing the PC
headgroup epitope similar to oxLDL. Colonies of the R36A strain
were harvested at mid-log phase after incubation at 37◦C on
blood agar plates and transferred to Todd-Hewitt plus 0.5%
yeast broth. The mid-log phase is characterized by an optical
density (OD) value of 0.425–0.45 at 600 nm. S. pneumoniae
were heat-inactivated at 60◦C for 30min; afterwards, no colonies
of this suspension were detected on blood agar plates, thus
confirming their inactivation. For freezer stocks of strain R36A,
small aliquots of S. pneumoniae atmid-log density were harvested
and suspended in Todd-Hewitt plus 80% sterile glycerol and
stored at−80◦C (32).
Mice and Immunization
Npc1nih mice were housed under standard conditions and
were given free access to food and water. A complementary
experiment with age-matched wildtype mice was performed
to confirm the phenotypical effect of the Npc1 mutation in
Npc1nih mice. Experiments were performed according to Dutch
laws and were approved by the Animal Experiment Committee
of Maastricht University. Npc1nih mice were derived from
heterozygous founders (C57BL/6 / Npc1nih).
The immunization protocol started in 2-week old Npc1nih
mice (male or female) fed a normal chow diet. Mice were divided
into 2 groups (n = 12 for both groups). One of the groups
received the equivalent of 108 colony-forming units of heat-
inactivated pneumococcal immunogen emulsified in 200 µl of
sterile 0.9% NaCl for the primary subcutaneous immunization;
subsequently, two intraperitoneal booster immunizations were
administered every 2 weeks (31). The control group received
NaCl injections. During the experiment, which lasted 5 weeks
in total, mice were given a normal chow diet. Blood from
the tail vein was collected at week 3 and 5. An overview of
the experimental set-up is given in Supplementary Figure S1.
During the course of the study, one control-treated Npc1nih
mouse died, and was therefore excluded from the experimental
analyses. All tissues were isolated and snap-frozen in liquid
nitrogen and stored at −80◦C or fixed in 4% formaldehyde/PBS.
The collection of blood and tissue specimens, RNA isolation,
cDNA synthesis and qPCR were determined as described
previously (18, 33, 34). Also the measurements of the
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autoantibody titers against IgG and IgM antibodies to CuOx-LDL
and PC-BSA have been described extensively (18).
Lipid Measurements
Total plasma cholesterol and triglyceride levels were
measured (1489232, Chol CHOD-PAP, Roche, Almere,
the Netherlands; 337-B, TG GPO-trinder, Sigma Aldrich,
Zwijndrecht, the Netherlands). Measurements were done
according to manufacturer’s protocols on a Benchmark 550
Micro-plate Reader (170-6750XTU, Bio-Rad, Veenendaal, the
Netherlands). For organ lipid analyses, ∼50mg of frozen liver
was homogenized for 30 s at 5,000 rpm in a closed tube with
5.0mm glass beads and 1.0ml SET buffer (Sucrose 250mM,
EDTA 2mM, and Tris 10mM) (35). Complete cell destruction
was done by two freeze-thaw cycles and 3 times passing through
a 27- gauge syringe needle and a final freeze-thaw cycle. Protein
content was measured with the BCA method (23225, Pierce,
Rockford, IL, United States). TG were measured as described
above. All analyses were performed according to manufacturers’
instructions.
Immunohistochemistry
Frozen liver sections (7µm) were fixed in acetone and blocked
for endogenous peroxidase by incubation with 0.25% of
0.03% H2O2 for 5min. Primary antibodies used were against
neutrophils (rat anti-mouse Ly6C, clone NIMP-R14), hepatic
macrophages (rat anti-mouse CD68, clone FA11), and infiltrated
macrophages and neutrophils (rat anti-mouse Mac-1 [M1/70]).
3-Amino-9-ethylcarbazole (AEC) was applied as color substrate
and hematoxylin for nuclear counterstain. Sections were enclosed
with Faramount aqueous mounting medium.
Paraffin-embedded cortical and cerebellar sections (4µm;
sagitally) were deparaffinized and stained with hematoxylin-
eosin (HE) and primary antibodies against Iba-1 and calbindin.
Sections were subjected to heat-mediated antigen retrieval
and blocking with 4% goat serum/PBS, after which they
were incubated with rabbit anti-Iba1 overnight. The following
day, sections were incubated with swine anti-rabbit, whose
signal was amplified with the VECTASTAIN R© Elite R© ABC
system and counterstained with a DAB solution. For calbindin
immunostaining, sections’ endogenous peroxidase activity was
blocked by incubating in 0.5% H2O2/methanol for 10min.
After performing heat-mediated antigen retrieval, sections were
incubated with rabbit anti-calbindin overnight. The following
day, sections were incubated with biotinylated goat anti-
rabbit antibody, whose signal was amplified by using the
VECTASTAIN R© Elite R© ABC system.
Pictures were taken with a Nikon digital camera DMX1200
and ACT-1 v2.63 software (Nikon Instruments Europe,
Amstelveen, The Netherlands).
Cerebellar Purkinje cells (calbindin) were counted and scored
in 10–20 microscopical views (original magnification, 200x).
Number of Purkinje cells was indicated as number of cells
per pixel (Adobe Photoshop CS2 v.9.0.). Scoring was performed
according to presence of Purkinje cells’ dendritic structure
(1, defined arborization structure; 2, intermediary; 3, lack of
arborization structure). Purkinje cells’ number and scoring are
derived from the average of independent observations from two
blinded researchers.
Cerebellar Purkinje cells’ HE histological staining was assessed
in 10 microscopical views (original magnification, 100x) by
quantifying HE staining using Fiji plugin of ImageJ software (v.
1.52 h).
Cortical microglia (Iba-1) were counted and scored in 12
microscopical views (original magnification, 400x) and indicated
as number of cells per field. Microglia were scored according
to their phenotype as follows: type 1 (characterized by small
cell bodies and long, thin fillaments); type 2 (thicker and less
numerous fillaments); type 3 (large cell body, no fillaments)
(Supplementary Figure S2) (36).Microglia numbers and scoring
are given as the average of independent analyses done by two
blinded researchers.
Hepatic foamy cells (HE) were assessed in five microscopical
views (original magnification, 200x) by an experienced
pathologist and given a score in arbitrary units (A.U). Splenic fat
accumulation (HE) was evaluated in three microscopical views
(original magnification, 200x) by quantifying the percentage of
positive area using Adobe Photoshop CS2 v.9.0.
Hepatic neutrophils (NIMP) and infiltrated macrophages and
neutrophil cells (Mac-1) were counted in six microscopical views
(original magnification, 200x) and were indicated as number of
cells per square millimeter (cells/mm2). Immunostainings for
hepatic macrophages (CD68) were evaluated by an experienced
pathologist and given a score in arbitrary units (A.U.).
Genotyping
Genotypes of animals were determined by PCR analysis of tail
DNA. Tails were clipped at postnatal day 6 and homogenized
in DirectPCR-Tail (Peqlab, Erlangen, Germany) supplemented
with a tenth part Proteinase K (Qiagen, Hilden, Germany).
Three hours of incubation at 56◦C and agitation at 1,000 rounds
per minute on a Thermo Mixer were followed by 45min of
heating at 85◦C to inactivate the proteinase. Samples were then
spun at full speed in a benchtop centrifuge for 1min. The PCR
reactions were performed with 0.5ml of the obtained extracts.
Each lysate underwent two PCRs; Primers gccaagtaggcgacgact
and catctactgggtctccatatgtat identified the wild-type allele and
primers gccaagtaggcgacgact and ttccaattgtgatctttccaa identified
the mutant allele. Both PCRs were carried out under similar
cycling conditions.
Pole Test
The pole test was performed as previously described with minor
modifications (37, 38). The mouse was placed head-upward on a
small platform on top of a vertical rough-surfaced pole (diameter
10mm; height 50 cm) and the time until the mouse descended
to the floor (locomotor activity time: TLA) was recorded with a
maximum duration of 120 s. Even if the mouse descended part of
the way and fell the rest of the way, the behavior was scored until
it reached to the floor. When the mouse did not turn downward
and instead dropped from the pole, TLA was considered as 120 s
because of maximal severity. The pole test was performed on 3
different days (day 18, 25, and 32), with 5 consecutive trials per
mouse.
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Accelerod (Accelerated Rotarod) Test
Balance and motor coordination of mice was evaluated using
accelerod performance on day 21 and day 33 of the experiment.
The accelerod system for mice was used under standard room
conditions. The apparatus consisted of a base platform and a
rotating rod with a grooved surface. Before accelerod testing,
mice were trained at 2 separate days (day 17 and 19 of the
experiment). On both training days, mice underwent 3 separate
training moments (separated 2 h from eachother) in which they
endured 3 trials with a constant speed of 18 revolutions per
minute for 120 s. When operated in the acceleration modus, the
rotation increased from 4 to 40 revolutions per minute in 30 s
steps within 5min. The performance was measured as the latency
to fall (s).
Statistical Analysis
Data were statistically analyzed by performing two-tailed non-
paired t-test, two-way ANOVA followed by Tukey’s post-hoc
correction and repeated measures two-way ANOVA followed by
Tukey’s post-hoc correction using GraphPad Prism version 6 for
Windows. Data were expressed as the mean and standard error of
the mean. Data were considered significantly different compared
to control-treatedNpc1nih mice, except for the analyses of rotarod
and pole test results, in which comparisons were made between
different time points among the same study groups. (∗p ≤ 0.05;
∗∗p< 0.01; ∗∗∗p< 0.001; ∗∗∗∗p< 0,0001).
RESULTS
Npc1nih Mice Recapitulate NPC1 Disease
Features and Display Elevated Anti-oxLDL
IgM Autoantibody Titers After
Immunization With Heat-Inactivated
Pneumococci
To assess the effects of the Npc1nih mutation, body, spleen
and liver weight were compared between control-treated
Npc1nih mice and age-matched wildtype mice. Whereas, total
spleen weight was reduced in Npc1nih mice compared to
wildtype mice, total liver weight was increased in Npc1nih
mice (Supplementary Table S1). As expected, body weight
of Npc1nih mice was reduced in comparison with age-
matched wildtype mice (Supplementary Table S1), reflecting
overall NPC1 disease burden. To determine whether anti-
oxLDL IgM autoantibodies have a protective effect in NPC1, 2
week-old Npc1nih mice were immunized with heat-inactivated
pneumococci, known to induce high anti-oxLDL IgM titers
dominated by T15-idiotypic IgM (18, 31). While total body
weight (Supplementary Figure S3A) and total liver weight did
not differ (Supplementary Figure S3B), total spleen weight was
decreased in immunized Npc1nih mice compared to control-
treated counterparts (Supplementary Figure S3C). As expected,
immunization resulted in a strong increase in plasma anti-
oxLDL antibody levels in Npc1nih mice (Figures 1A,B). Only
weak IgG responses were observed, which is in line with previous
reports showing pneumococcal immunizations triggering an
IgM-dominated thymus-independent type-2 response highly
specific for phosphorylcholine (PC) (Figures 1C,D).
Delayed Motor Skill Degeneration and
Improved Neuroinflammation and Cerebral
Morphology in Immunized Npc1nih Mice
Motor skill degeneration is a common neurological feature
of NPC1, due to the progressive loss of Purkinje cells. To
determine the effects of the pneumococcal immunization on
motor function of Npc1nih mice, pole and rotarod tests were
performed throughout the study period. As expected, Npc1nih
mice performance on both tests was consistently worse than their
wildtype counterparts (Supplementary Table S1), confirming
NPC1 disease burden onmotor function. By the end of the study,
control-treated Npc1nih mice took significantly longer time to
descend the pole (Figure 2A), whereas locomotor activity time
(TLA) of immunizedNpc1nih mice remained stable over the entire
experiment. Additionally, the motor function scores obtained
for the pole test strongly correlate with the levels of plasma
anti-oxLDL IgM autoantibodies, suggesting a link between
the amount of circulating anti-oxLDL IgM autoantibodies
and overall motor performance (Supplementary Figure S4).
While the performance of both control-treated and immunized
Npc1nih mice on the rotarod test worsened significantly over
time (Figure 2B), the observed performance decay was more
prominent in the control-treated Npc1nih mice. These results
indicate that motor function deterioration over time was
decreased in immunized Npc1nih mice.
Next, we investigated whether pneumococcal immunization
affects Purkinje cells in Npc1nih mice. In line with motor
skill function results, the integrity of cerebella of control-
treated Npc1nih was severely compromised, whereas immunized
Npc1nih mice retained more of their cerebellar structure
(Figures 2C,D and Supplementary Figure S5A). Furthermore,
Purkinje cells of untreated Npc1nih mice displayed increased
hematoxylin and eosin (HE) staining intensity, suggesting
higher activation levels due to damage (Figure 2E, upper
panel; Figure 2F and Supplementary Figure S5B). Overall,
these results indicate that pneumococcal immunization delays
cerebellar neurodegeneration in Npc1nih mice. In addition
to severe cerebellar neurodegeneration, cortical immune cells
were observed in control-treated Npc1nih mice, in contrast
with immunized Npc1nih mice, suggesting higher levels of
neuroinflammation in the control-treated group (Figure 2E,
lower panel and Supplementary Figure S5B).
We further analyzed the effects of pneumococcal
immunization on neuroinflammation by examining microglial
cells using immunohistochemical staining for Iba-1 (Figure 2G).
While no differences were observed in total number of microglia
(Figure 2H), microglia of immunized Npc1nih mice exhibited
larger cell bodies and shorter, less ramified processes, suggesting
a change in microglia phenotype following pneumococcal
immunization (Figure 2I).
Finally, we analyzed cerebral and cerebellar gene expression
analysis of the inflammatory markers C-X-C motif chemokine
10 (Cxcl10), chemokine (C-C motif) ligand 3 (Ccl3), and
cluster of differentiation 68 (Cd68). Immunization of Npc1nih
mice reduced expression of all inflammatory markers in
the cerebrum, with the exception of Ccl3, in which a trend
suggesting decreased expression was observed (Figure 2J).
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FIGURE 1 | IgM autoantibodies in Npc1nih mice receiving control or heat-inactivated pneumococci injections. (A–D) IgM and IgG antibodies against oxLDL (CuOx
and PC-BSA) were measured in the plasma of control (n = 11) and pneumococci-immunized (n = 12) Npc1nih mice. Data are expressed as relative light units
RLU/100ms and were triplicate determinations. ***Indicates p < 0.001 compared to NaCl-treated Npc1nih mice by use of two-tailed unpaired t-test. n = 11–12 mice
per group. All error bars are SEM.
In addition, while expression of Cxcl10 and Cd68 in the
cerebellum tended to be decreased, expression of Ccl3 was
reduced in the cerebellum of immunized Npc1nih mice
(Figure 2K). Furthermore, gene expression of cathepsin
D (Ctsd), a marker previously linked to NPC1 severity
in mice (39, 40), and Npc2, which is known to bind to
cholesterol in the lysosome, were reduced in the cerebrum
of Npc1nih mice that received the immunization, indicating
an improved neurological phenotype after immunization.
Notably, cerebral and cerebellar expression of several of
these markers correlated with the plasma anti-oxLDL IgM
autoantibody levels (Supplementary Figure S4), underlining
the link between the neurological phenotype and anti-oxLDL
IgM autoantibody levels. Altogether, these results indicate
beneficial effects of immunization with heat-inactivated
pneumococci on the neurological phenotype of Npc1nih
mice.
Decreased Hepatic and Splenic Lipid
Levels in Immunized Npc1nih Mice
To determine whether immunizing Npc1nih mice with heat-
inactivated pneumococci influences hepatic lipid levels,
biochemical assessment of hepatic cholesterol and triglycerides
was performed. Npc1nih mice showed an increase in plasma
and liver cholesterol levels compared to age matched wildtype
mice (Supplementary Table S1). Seven week-old Npc1nih
mice that received the immunization demonstrated reduced
levels of hepatic total cholesterol (Figure 3A) and triglycerides
(Figure 3B) compared to control-treated Npc1nih mice, though
the latter only showed a trend. In line, HE-staining of the
liver confirmed the decrease of lipid levels in hepatocytes and
the reduced foamy appearance of hepatic macrophages in
immunized Npc1nih mice (Figures 3C,D). Relevantly, hepatic
gene expression levels of acetyl-CoA acetyltransferase 2 (Acat2),
the enzyme responsible for cholesterol esterification, were
elevated in immunized Npc1nih mice, suggesting increased
cholesterol esterification upon immunization (Figure 3E).
In contrast, no differences were observed in plasma lipid
levels between control-treated and immunized Npc1nih mice
(Figures 3F,G). To obtain a more detailed view on hepatic
lipid distribution, electron microscopy analysis was performed
(Figure 3H). Though both control and immunized Npc1nih
mice showed the NPC1 characteristics of hepatic lipid
inclusions (blue circles) and vacuoles with electron-dense
material (asterisk), immunized Npc1nih mice demonstrated
a less foamy appearance of hepatic macrophages (arrow). In
contrast with these observations, no differences were observed
in lipid accumulation in the spleen of immunized Npc1nih
mice and control-treated Npc1nih mice (Figures 3I,J). Overall,
these results suggest improved hepatic lipid metabolism after
increasing anti-oxLDL IgM autoantibody levels in Npc1nih
mice.
Frontiers in Immunology | www.frontiersin.org 5 January 2019 | Volume 9 | Article 3089
Houben et al. Pneumococcal Immunization in NPC1
FIGURE 2 | Neurological parameters. (A) Locomotor activity time (TLA ) of control and immunized Npc1
nih mice as measured by the pole test at day 18, 25, and 32 of
the experiment. (B) Rotarod performance of control and immunized Npc1nih mice at day 19 and 33 of the experiment. (C,D) Representative pictures and scoring of
calbindin staining of Purkinje cells in cerebellum. (E) General histology of the brain by HE staining. Arrows indicate Purkinje cells (top panels) and immune cells (bottom
left panel). (F) Quantification of Purkinje HE staining density. (G–I) Representative pictures, quantification, and scoring of Iba-1 staining of cortical microglia (type 1,
type 2, and type 3). (J,K) Gene expression analysis of Cxcl10, Ccl3, Cd68, Npc2, and Ctsd in cerebrum and cerebellum. Data are shown relative to NaCl-treated
Npc1nih mice for all analyses except for pole test and rotarod data, where comparisons were made between different time points within the same experimental group.
*Indicates p < 0.05, **p < 0.01, and ****p < 0.0001 by use of two-tailed unpaired t-test or repeated measures two-way ANOVA with Tukey’s post-hoc correction (in
pole test and rotarod data analysis only). n = 11–12 mice per group for pole and rotarod tests and n = 5 mice per group for gene expression data. All error bars are
SEM.
Improved Hepatosplenic Phenotype in
Immunized Npc1nih Mice
To determine whether immunization of Npc1nih mice affects
hepatic inflammation, hepatic cryosections were stained for
the inflammatory cell markers NIMP (neutrophils), CD68
(resident macrophages) and Mac-1 (infiltrated macrophages
and neutrophils). The number of infiltrated neutrophils and
macrophages in control-treated Npc1nih mice was increased
compared to wildtype mice, confirming increased hepatic
inflammation in Npc1nih mice (Supplementary Table S1).
Following pneumococcal immunization, the number
of neutrophils and resident macrophages were reduced
Npc1nih mice (Figures 4A,B,D). Although the number
of infiltrated neutrophils and macrophages (Figure 4C)
and HE-scoring of hepatic inflammation (Figure 3C and
Supplementary Figure S6) did not reach statistical significance
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FIGURE 3 | Parameters of lipid metabolism. (A,B) Hepatic total cholesterol and total triglyceride levels of control and immunized Npc1nih mice (n = 11 in both
experimental groups). (C,D) Scoring and representative pictures of hepatic HE-staining (200x magnification). (E) Hepatic gene expression analysis of Acat2. Data is
shown relative to NaCl-treated Npc1nih mice. (F,G) Plasma total cholesterol and total triglyceride levels of 7 week-old control and immunized Npc1nih mice. (H)
Electron microscopy of livers of control and immunized Npc1nih mice. Arrows indicate a hepatic macrophage, blue circles indicate lipid inclusions, and asterisks
indicate vacuoles with electron-dense material. (I,J) Representative pictures and quantification of HE staining of the spleen (100x magnification). *Indicates p < 0.05
and **p < 0.01 compared to NaCl-treated Npc1nih mice by use of two-tailed unpaired t-test. n = 11–12 mice per group. All error bars are SEM.
between study groups, a trend toward reduction of these
parameters following immunization was observed. To confirm
these histological findings, hepatic gene expression analysis
was performed on the inflammatory markers tumor necrosis
factor alpha (Tnfα), chemokine (C-C motif) ligand 2 (Ccl2),
macrophage inflammatory protein 2 (Mip2). Tnfα and Ccl2
expression levels were significantly reduced in immunized
Npc1nih mice compared to non-immunized Npc1nih mice
(Figure 4E). The expression of Mip2 and Ctsd, a marker for
disease severity, showed no difference between control-treated
and immunized Npc1nih mice, although a trend suggesting
reduced expression following immunization was observed
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FIGURE 4 | Hepatic parameters. (A–D) Liver sections were stained for neutrophils (NIMP), hepatic macrophages (CD68), and infiltrated macrophages and neutrophils
(Mac-1). NIMP and Mac-1 positive cells were counted, whereas the CD68 stainings were scored. Panel D shows representative images of the NIMP staining. (E)
Hepatic gene expression analysis of inflammatory markers Ccl2, Tnfα, and Mip2. Data are shown relative to NaCl-treated Npc1nih mice. (F) Quantification of hepatic
apoptosis, assessed by scoring of HE-staining of the liver. *Indicates p < 0.05 compared to NaCl-treated Npc1nih mice by use of two-tailed unpaired t-test. n =
11–12 mice per group. All error bars are SEM.
(Figure 4E). As increased hepatic apoptosis is linked to
inflammation and damage of the liver (41), hepatic apoptosis
was also assessed. The amount of apoptotic cells, as quantified
by HE-staining, was reduced upon immunization (Figure 4F),
indicating an improvement of the NPC1 disease phenotype in
the liver after pneumococcal immunization. Additionally, similar
results were observed in the spleen, showing reduced expression
of inflammatory markers, although in the case of Tnfα, only a
trend was observed (Figure 5). Finally, hepatosplenic expression
of most of these markers correlated with the plasma anti-
oxLDL IgM autoantibody levels (Supplementary Figure S4),
underlining the link between the systemic improvements and the
anti-oxLDL IgM autoantibody levels. Altogether, these findings
indicate an improved hepatosplenic phenotype in Npc1nih mice
that received the heat-inactivated pneumococci immunization,
supporting its potential as treatment for NPC1 disease.
DISCUSSION
Due to severity of symptoms, delayed diagnosis and restricted
therapeutical options, NPC1 disease patients suffer from
a gradual impairment in quality of life and premature
death. NPC1 disease commonly manifests through systemic
symptoms, such as liver and spleen dysfunction, which
precede neurological symptoms (epilepsy, movement disorder,
dementia, among others). In this study, we show that
heat-inactivated pneumococci immunization improves both
systemic and neurological symptoms, including motor function,
neurodegeneration, neuro- and systemic inflammation in a
mousemodel of NPC1 disease. In light of these promising results,
we propose pneumococcal immunization as a novel therapeutic
tool to ameliorate NPC1 disease severity, potentially in
combination with treatments such as Miglustat and cyclodextrin
(9, 42).
Although the role of oxLDL in neurodegenerative diseases
has not been extensively investigated, oxLDL is involved in
the pathogenesis of NASH and atherosclerosis, two diseases
that share pathological mechanisms with NPC1 disease (19,
20, 43–46). Currently, there is no definite consensus on the
benefits of targeting oxLDL by increasing anti-oxLDL antibodies
in atherosclerosis, as some studies suggest that this approach
increases inflammation and exacerbates disease severity (47–
49). However, it should be noted that, in these studies, no
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FIGURE 5 | Parameters of spleen inflammation. Hepatic gene expression
analysis of Tnfα, Cd68, IL-6, and Ctsd. Data are shown relative to
NaCl-treated Npc1nih mice. *Indicates p < 0.05 and **p < 0.01 compared to
NaCl-treated Npc1nih mice by use of two-tailed unpaired t-test. n = 11–12
mice per group. All error bars are SEM.
distinction was made between classes and idiotypes of anti-
oxLDL antibodies. Although a study from Smook et al (50)
found no correlation between anti-oxLDL IgM autoantibody
levels and advanced atherosclerotic lesion formation, this study
could not establish whether anti-oxLDL IgM antibodies are anti
or pro-atherogenic, and several other in vivo reports have found
increased anti-oxLDL IgM antibody levels to be beneficial (51,
52). Thus, it is likely that the reported pathogenic effects of
anti-oxLDL antibodies are due to the production of anti-oxLDL
IgG, rather than IgM, antibodies. In atherosclerosis and NASH,
pneumococcal immunization has been shown to ameliorate
inflammation and disease severity (18, 20, 31), suggesting that
this treatment may be beneficial to the systemic components of
NPC1.
Although no effects were observed on splenic lipid
accumulation following pneumococcal immunization,
expression of several inflammatory genes was improved in
the spleen of immunized Npc1nih mice. Of note, in this study,
we observed reduced spleen weight in control-treated Npc1nih
mice compared to wildtype mice instead of characteristic
splenomegaly of NPC1 disease, indicating that this model does
not recapitulate the spleen NPC1 disease phenotype. In contrast
to spleen observations, liver weight and cholesterol accumulation
as well as hepatic inflammation were increased in control-treated
Npc1nih mice compared to wildtype counterparts. Following
pneumococcal immunization, liver apoptosis, hepatosplenic
inflammation and hepatic cholesterol accumulation were
decreased in immunized Npc1nih mice, although the latter
effects were of low magnitude. In addition to targeting oxLDL,
immunization with heat-inactivated pneumococci is also known
to improve clearance of apoptotic cells, due tomolecular mimicry
between apoptotic cells and S. pneumoniae (31). Indeed, after
immunization, Npc1nih mice displayed lower levels of apoptotic
liver cells. Therefore, the beneficial effects of heat-inactivated
pneumococci immunization in our study can partly derive from
increased clearance of apoptotic cells.
As expected, control-treated Npc1nih mice showed motor
function deficits as assessed by the pole and rotarod tests,
confirming neurological impairments in these mice compared
to wildtype mice. In this study, unlike control-treated Npc1nih
mice, the performance of immunized Npc1nih mice on the pole
test remained unchanged over time. Additionally, immunized
Npc1nih mice displayed less prominent decay on rotarod test
performance compared to their control-treated counterparts.
It should be noted that, unlike the beam walking or the
catwalk test, several neuronal circuits are involved in pole
and rotarod test performance (53). As such, we are unable to
pinpoint the specific skills that were improved by pneumococcal
immunization. Nonetheless, our results indicate an overall
improvement in motor function decay following pneumococcal
immunization in Npc1nih mice, in line with observed reduction
in neuroinflammation and cerebellar damage.
The mechanisms leading to improved neurological features
in Npc1nih mice following pneumococcal immunization are
unclear. IgM antibodies are large molecules and are thus usually
precluded from the nervous system due to the blood brain barrier
(BBB). As such, whether peripheral immunization strategies can
be effective in the nervous system is a controversial matter.
Nonetheless, peripheral immunization in Alzheimer’s disease and
amyotrophic lateral sclerosis has been shown to elicit beneficial
effects in the nervous system with as little as 0.1% antibody
passage through the BBB (54, 55). Furthermore, it has been
proposed that antibodies in the nervous system facilitate the
corresponding ligand eﬄux to the periphery, thus contributing
to its clearance (55). As such, it is possible that the neurological
improvements observed in this study derive from anti-oxLDL
IgM autoantibody-mediated oxLDL clearance to the periphery
and/or prevention of oxLDL uptake by microglia scavenger
receptors, as has been proposed for macrophages (56, 57). On the
other hand, live S. pneumoniae can cross the BBB due to certain
membrane-surface proteins (58) that may be retained after heat-
inactivating the bacteria. Although more thorough analyses are
required to derive conclusions regarding microglia activation
state, following pneumococcal immunization we observed a shift
in microglia morphology that is commonly associated with a
phenotypical change in these cells (59). While we are unable to
pinpoint whether this is a response to interaction of microglia
with anti-oxLDL IgM autoantibodies, complement activation
or heat-inactivated pneumococci recognition, the latter option
is unlikely, as previous reports suggest that heat-inactivated
S. pneumoniae are non-immunogenic in the nervous system
(60). Of note, in vitro and in vivo studies have shown that
endothelial cells in the BBB are susceptible to oxLDL-induced
cytotoxicity (61–63). Therefore, it is possible that high levels
of plasma oxidized cholesterol products and oxLDL in NPC1
disease increase BBB permeability and exacerbate neurological
symptoms, a concept that has previously been proposed in
Alzheimer’s disease (63). In support of these observations, the
observed immune cells in the cortex of untreated Npc1nih
mice may result from a compromised BBB integrity. As such,
improved neurologic symptoms following immunization in
NPC1 disease could further derive from an improved BBB
phenotype and function.
Persistent systemic- and neuroinflammation are well-
described characteristics of NPC1 disease. While, under
physiological conditions, inflammatory processes encourage
the clearance of toxic compounds and the repair of injured
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tissues, the inability to overcome a pathological stimulus causes
the persistent inflammatory response to become detrimental.
Therefore, reducing inflammation and its associated pathological
burden might be a promising approach to reduce NPC1 disease
severity. In line with this view, administering non-steroidal
anti-inflammatory drugs (NSAID) has been shown to improve
motor function, body weight and even survival in a mouse model
for NPC1 disease (64). Based on these findings, one can speculate
on the direct role of inflammation in NPC1 disease severity
and progression, despite it not being the primary cause of the
disease. Similarly, though also initially not acknowledged as an
essential disease component, inflammation is now accepted as
a key component in disorders such as atherosclerosis (65), and
Alzheimer’s disease (66). Therefore, the role of inflammation in
NPC1 disease and its usefulness as a therapeutical target should
be further investigated.
Currently, therapeutic interventions for NPC1 disease focus
on symptom management, and no curative treatments are
available (67). As several mechanisms downstream of lysosomal
lipid accumulation contribute to NPC1 disease pathology,
interventions targeting different key features of NPC1 disease are
likely to have increased benefits compared to mono-therapeutic
startegies. In line with this rationale, in vitro and in vivo studies
have analyzed the effects of combining therapies to improve
cellular lipid accumulation, oxidative stress, inflammation and
intracellular calcium homeostasis (64, 68). Overall, such studies
found that combined therapies outperform the use of single
compounds, highlighting the benefits of tackling different
pathological mechanisms in NPC1 disease. For instance, the
effects of improved cellular lipid accumulation, considered to
be at the root of NPC1 disease pathology, are amplified when
combined with anti-inflammatory and antioxidant compounds
(68). As such, the investigation of pneumococcal immunization
in combination with direct lysosomal lipid mobilizers (i.e.,
cyclodextrin) may be an attractive future approach for NPC1
disease patients.
Despite the promising features of pneumococcal vaccination,
some points should be addressed before it can be used as a
treatment for NPC1 disease. Although the impact of spleen
damage on the immune system of NPC1 disease patients has
yet to be analyzed, it is likely that the latter is compromised
to some extent, which may in turn decrease the efficacy of
immunotherapy. Furthermore, it was not yet assessed whether
pneumococcal immunization is efficient in the context of
NPC1 disease not just as a treatment but also as a preventive
tool. In addition, in this study, Npc1nih mice received two
booster pneumococci immunizations, whereas pneumococcal
vaccination in humans is usually performed once every several
years, which may not be enough for therapeutically relevant
oxLDL clearance (69). Nevertheless, it is worth taking into
consideration that one of the most common manifestations
of NPC1 is dysphagia, whose complications range from
malnutrition to lung infections, mainly, bronchopneumonia (70–
73). The fact that bronchopneumonia is a major cause of death in
NPC1 disease patients is therefore another compelling argument
for using pneumococcal immunization in these patients. The use
of pneumococcal vaccinations against pneumonia is widespread
(74–78). Furthermore, due to its long practice in the clinic, many
optimizations of the vaccine have taken place, guaranteeing its
safety even in vulnerable individuals such as pregnant women,
young children, and the elderly (75–77). It should be noted that
different S. pneumoniae strains as well as other bacteria, possess
the phosphorylcholine epitope that triggers the production of
anti-oxLDL IgM autoantibodies by means of molecular mimicry
(31, 79). Nevertheless, it was so far not investigated whether
immunization using these bacteria also elicits beneficial effects on
lipid metabolism and inflammation. Furthermore, in this study,
some of the phenotypical improvements, although statistically
significant, were of low magnitude (i.e., hepatic cholesterol
accumulation). Whether these effects can be enhanced by
combining pneumococcal immunization with other NPC1
disease treatments or by using different immunogens should be
explored in the future. Overall, considering the promising results
in this study, further research is warranted to fully assess the
most efficient way to modulate anti-oxLDL immune responses
via pneumococcal vaccination in NPC1 disease patients.
FINAL REMARKS
For the first time, we demonstrate that increasing anti-oxLDL
IgM autoantibodies ameliorates motor function decay, neuro-
and hepatic inflammation as well as hepatic cholesterol
metabolism in NPC1 disease. In light of the present findings,
we propose pneumococcal immunization, potentially in
combination with other available treatments, as a novel
therapeutic tool for NPC1 disease.
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